Pricing Log in Create free account

Galectin Therapeutics Inc. (GALT) vs X4 Pharmaceuticals, Inc. (XFOR)

Galectin Therapeutics Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Galectin Therapeutics Inc. and X4 Pharmaceuticals, Inc. are of similar size ($304.4M and $301.0M). Galectin Therapeutics Inc. has the higher net margin (0.00% vs −474.7%) and the higher return on invested capital (0.00% vs −178.2%). Across the 13 metrics below, Galectin Therapeutics Inc. leads on 8 and X4 Pharmaceuticals, Inc. on 5.

Valuation

Metric GALT XFOR Biotechnology median
P/E n/m n/m 10.60
P/S n/m 23.50 9.40
P/B n/m 2.87 2.13
Price to free cash flow n/m 16.91 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 17.02 9.02
Earnings yield (13.69%) (21.26%) (32.88%)
Free cash flow yield (7.68%) 5.91% (23.13%)

Profitability

Metric GALT XFOR Biotechnology median
Gross margin 0.00% 81.77% 68.51%
Operating margin 0.00% (473.95%) 0.00%
Net margin 0.00% (474.74%) 0.00%
Free cash flow margin 0.00% (478.16%) 0.00%
Return on equity 21.69% (80.32%) (51.96%)
Return on assets (184.22%) (40.73%) (46.06%)
Return on invested capital 0.00% (178.23%) 0.00%

Growth

Metric GALT XFOR Biotechnology median
Revenue growth (TTM) — (50.08%) 6.76%
EPS growth (last fiscal year) 36.84% 67.23% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GALT XFOR Biotechnology median
Debt to equity (0.76) 0.55 0.00
Current ratio 0.10 13.22 4.97
Net debt to EBITDA (5.79) 2.06 1.01

Dividend

Metric GALT XFOR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GALT XFOR Biotechnology median
Market cap 301.04m 304.38m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack